BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home
»
Newsletters
» BioWorld
BioWorld
May 3, 2005
View Archived Issues
GSK Buying Corixa: $300M Brings MPL Facility, More
Vaccine partner GlaxoSmithKline plc plans to buy Corixa Corp. for $300 million in cash, paying $4.40 per share - a 48 percent premium to the closing price on April 28, the day before the deal was made public. (BioWorld Today)
Read More
Flurizan Misses Major Phase II Endpoints, But Positives Seen
Read More
Biotech Model Broken; Now What Can Be Done About It?
Read More
Conforma Adding $11M To Series C For Hsp90 Drugs
Read More
CTI Aims For Xyotax NDA Despite Missed Endpoints
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
